Zero Circle and Wasabi Technologies Partner on New Sustainability Tools for Cloud Storage
Zero Circle, a sustainable finance marketplace, and Wasabi Technologies, the hot cloud storage company, have partnered to develop a suite of sustainability-focused solutions for cloud storage that give businesses the data they need to make decisions that reduce their environmental impact.
Wasabi cloud storage integrated Zero Circle’s invoice-based carbon footprint calculator to give customers transparency and real-time assessment of their carbon footprint. Customers can upload their Wasabi invoice to Zero Circle’s carbon calculator to determine their estimated CO2 footprint based on actual data stored in a Wasabi storage region, increasing the accuracy of their ESG benchmarking with their peers and helping them make more sustainable business decisions.
According to the Wasabi 2024 Global Cloud Storage Index, sustainability ranks among the top three most important considerations for buyers when choosing a cloud storage service. Factors like ESG commitments, energy-efficient architecture design, and native tools for carbon footprint calculation are all increasingly important to modern enterprises as they adopt cloud infrastructure services. As a result, the survey found that cloud service providers must deliver accurate, reliable tools, metrics, and programs to meet customer expectations.
This joint initiative leverages Zero Circle's deep expertise in sustainability and product carbon footprint measurement with Wasabi's leadership in cloud storage to drive sustainability in the cloud storage industry and create innovative solutions that support businesses with their sustainability initiatives. The solution's unique features and flexibility make it a powerful resource for companies seeking to measure and track their cloud sustainability, such as real-time emissions calculations integrated directly into the purchases from supply chain partners.
“Partnering with Zero Circle underscores Wasabi’s dedication to providing top-tier, sustainable cloud storage solutions,” said David Boland, vice president of cloud strategy at Wasabi Technologies. “Zero Circle's carbon footprint calculation has already enabled Wasabi, our partners, and customers to gain a deeper understanding of our environmental impact. By integrating this solution into our supply chain, we are amplifying these benefits for everyone involved.”
"Announcing our collaboration with Wasabi marks a significant step in advancing environmental sustainability within the cloud storage sector,” said Hemanth Setty, founder and CEO of Zero Circle. “This partnership leverages our combined strengths and underscores our mutual dedication to fostering a more sustainable future, paving the way for innovative and groundbreaking solutions.”
The carbon footprint solution is now available to all Wasabi customers. The Zero Circle – Wasabi collaboration will also explore other eco-friendly initiatives, such as renewable energy procurement and carbon offset programs in an effort to further reduce environmental impact of cloud storage.
Additional Resources:
- For more information on Wasabi’s work with Zero Circle, visit wasabi.com/sustainability.
- To try Zero Circle’s invoiced-based carbon footprint calculator for Wasabi, visit https://cust.zerocircle.eco/wasabi.
- Join Wasabi, Zero Circle, and 451 Research July 16 at 1 p.m. ET/10 a.m. PT to learn how establishing sustainability goals for IT can help your business meet regulatory compliance more quickly. Read more details here.
About Zero Circle
Zero Circle is a green finance marketplace that simplifies access to green capital for mid-tier businesses. Its AI-powered platform streamlines sustainability assessments and reporting and automates financial and sustainability KPIs to incentivize green financing. The company helps its customers finance and build sustainable practices by tracking, managing, and reporting sustainability and financial performance with lenders, partners, and customers.
Click here to learn more about Zero Circle or follow them on LinkedIn and Twitter.
About Wasabi Technologies
Recognized as one of the technology industry’s fastest growing companies, Wasabi is on a mission to store the world's data by making cloud storage affordable, predictable and secure. With Wasabi, visionary companies gain the freedom to use their data whenever they like without being hit with unpredictable fees or vendor lock-in. Instead, they’re free to build best-of-breed solutions with the industry’s fastest-growing ecosystem of independent cloud application partners. Customers and partners all over the world trust Wasabi to help them put their data to work so they can unlock their full potential. Visit wasabi.com to learn more.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240710254246/en/
Contacts
Lindsay Daly, Director of Corporate Communications
press@wasabi.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 10:00:00 CET | Press Release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in
Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 10:00:00 CET | Press Release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration
Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 10:00:00 CET | Press Release
Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press Release
Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity. Pimicotinib, a colony stimulating factor-1 receptor (CSF-1R) inhibitor developed by Abbisko Therapeutics Co., Ltd., Shanghai, China, is the first Chemical Drug Class 1 approved in China for the treatment of TGCT. “We are continuing to deliver on our commitment to improving the lives of patients with rare tumors with this first-in-the-world regulatory approval of pimicotinib,” said Danny Bar-Zohar, CEO Healthcare and Member of the Executive Board of Merck. “This approval is a significant step forward in further strengthening our leadership in rare tumors, while offering patients the opportunity to change the course of
Incyte Japan Announces Approval of Minjuvi ® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press Release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom